Citations

Clear

511 citation(s) found for "Seth, N".

Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT #02844816).
Lucia, Scott, Lowrance, William T., Koshkin, Vadim S. , Bivalacqua, Trinity J. , Kassouf, Wassim , Bangs, Richard Carlton, Plets, Melissa , Black, Peter C. , Tangen, Catherine M. , Singh, Parminder Pal , McConkey, David James , Stratton, Kelly , Sharon, Elad , Porten, Sima P. , Lerner, Seth P. , Thompson, Ian M.

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: 5022-5022

10.1200/jco.2020.38.15_suppl.5022 Get It

5022 Background: Radical cystectomy (RC) is the standard of care for patients with BCG-unresponsive high risk non-muscle invasive bladder cancer (NMIBC), but many patients are unfit for surgery or elect bladder preservation. Based on the reported efficacy of atezolizumab in metastatic urothelial carcinoma and the known expression of PD-L1 in NMIBC after BCG therapy, this trial was designed to evaluate the activity of atezolizumab in BCG-unresponsive high risk NMIBC. Methods: This single arm phase II registration trial testing systemic atezolizumab (1200 mg IV) every 3 weeks for one year aimed to enroll 135 (70 CIS and 65 non-CIS) eligible patients with histologically proven BCG-unresponsive high risk NMIBC who were unfit for or declined RC. Here we report on the subset with CIS (with or without concomitant Ta/T1) among patients who received at least one protocol treatment. The primary endpoint was pathological complete response (CR) rate at 6 months as defined by mandatory biopsy with a null hypothesis of 30% and alternative of 50% with a 1-sided alpha = 0.05 and 96% power. The 3 month CR rate, defined by cytology, cystoscopy and for-cause biopsy, is reported here as a secondary endpoint, in addition to safety. Results: Seventy-five eligible CIS patients were enrolled. Two received no treatment and are not evaluable. Of 73, median patient age was 73.4 years and median number of prior BCG doses was 12. Concomitant Ta/T1 tumor was found in 30 (41.1%) patients, including T1 disease in 16 (21.9%). A CR was observed in 30 (41.1%; 95% CI 29.7%, 53.2%) patients at 3 months and 19 (26.0%; 95% CI 16.5%, 37.6%) at 6 months. Any possibly or probably treatment-related adverse event (AE) was observed in 61 (83.6%) patients. The most frequent AEs were fatigue 36 (49.3%), pruritis 8 (11.0%), hypothyroidism 8 (11.0%), and nausea 8 (11.0%). Grade 3-5 AEs occurred in 9 (12.3%) patients and there was one treatment-related death (myasthenia gravis with respiratory failure and sepsis). Conclusion: The observed response to atezolizumab at 3 and 6 months in patients with BCG-unresponsive CIS was similar to that reported in recent similar trials and meets the benchmark for initial CR defined by the FDA guidance. This trial provided no new safety concerns. The duration of response will determine if this is a suitable treatment option for patients with BCG-unresponsive high risk CIS. Clinical trial information: 02844816 .
Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases
Brazauskas, Ruta , Tecca, Heather R. , Bo‐Subait, Stephanie, Buchbinder, David , Battiwala, Minoo, Phelan, Rachel , Broglie, Larisa , Abraham, Allistair , Keating, Amy K. , Daly, Andrew , Wirk, Baldeep , Alter, Blanche P. , Üstün, Celalettin , Freytes, César O. , Beitinjaneh, Amer , Duncan, Christine , Copelan, Edward A. , Hildebrandt, Gerhard , Murthy, Hemant S. , Auletta, Jeffery J. , Page, Kristin , Vrooman, Lynda M. , Norkin, Maxim , Byrne, Michael , Kamani, Naynesh , Rezvani, Andrew R. , Farhadfar, Nosha , Mehta, Parinda A. , Hematti, Peiman , Shaw, Peter J. , Kamble, Rammurti T., Schears, Raquel M. , Hayashi, Robert J. , Mayo, Samantha , Rotz, Seth J. , Badawy, Sherif M. , Ganguly, Siddhartha , Pavletic, Steven Z. , Prestidge, Tim , Inamoto, Yoshihiro , Shaw, Bronwen E. , Satwani, Prakash , Battiwalla, Minoo , Schears, Raquel, Murthy, Hemant S , Badawy, Sherif M , Broglie, Larisa A , Battiwalla, Minoo , Auletta, Jeffery J , Hematti, Peiman , Kahn, Justine M , Flowers, Mary E.D. , Savani, Bipin N. , George, Biju , Lazarus, Hillard M. , Myers, Kasiani , Williams, Kirsten M. , Díaz, Miguel Ángel , Bhatt, Neel S. , Olsson, Richard F. , Gale, Robert Peter , Chhabra, Saurabh , Nishihori, Taiga , Agrawal, Vaibhav , Hogan, William J.

Mayo Clinic

Blood Advances | May 12, 2020 | Volume: 4 | Issue: 9 | Pages: 2084-2094

10.1182/bloodadvances.2019000839 | PMID 32396620 Get It

Abstract We examined the risk of subsequent neoplasms (SNs) and late mortality in children and adolescents undergoing allogeneic hematopoietic cell transplantation (HCT) for nonmalignant diseases (NMDs). We included 6028 patients (median age, 6 years; interquartile range, 1-11; range, <1 to 20) from the Center for International Blood and Marrow Transplant Research (1995-2012) registry. Standardized mortality ratios (SMRs) in 2-year survivors and standardized incidence ratios (SIRs) were calculated to compare mortality and SN rates with expected rates in the general population. Median follow-up of survivors was 7.8 years. Diagnoses included severe aplastic anemia (SAA; 24%), Fanconi anemia (FA; 10%), other marrow failure (6%), hemoglobinopathy (15%), immunodeficiency (23%), and metabolic/leukodystrophy syndrome (22%). Ten-year survival was 93% (95% confidence interval [95% CI], 92% to 94%; SMR, 4.2; 95% CI, 3.7-4.8). Seventy-one patients developed SNs (1.2%). Incidence was highest in FA (5.5%), SAA (1.1%), and other marrow failure syndromes (1.7%); for other NMDs, incidence was <1%. Hematologic (27%), oropharyngeal (25%), and skin cancers (13%) were most common. Leukemia risk was highest in the first 5 years posttransplantation; oropharyngeal, skin, liver, and thyroid tumors primarily occurred after 5 years. Despite a low number of SNs, patients had an 11-fold increased SN risk (SIR, 11; 95% CI, 8.9-13.9) compared with the general population. We report excellent long-term survival and low SN incidence in an international cohort of children undergoing HCT for NMDs. The risk of SN development was highest in patients with FA and marrow failure syndromes, highlighting the need for long-term posttransplantation surveillance in this population.
Clinical outcomes of patients with advanced synovial sarcoma or myxoid/round cell liposarcoma treated at major cancer centers in the United States
Somaiah, Neeta , Araujo, Dejka M. , Druta, Mihaela , Tine, Brian A. Van , Chawla, Sant P. , Seetharam, ­Mahesh , Okuno, Scott H. , Bohac, Chet, Yurasov, Sergey , Attia, Steven , Somaiah, Neeta , Van Tine, Brian A , Pollack, Seth M. , Burgess, Melissa , Chen, Michael

Mayo Clinic

Cancer Medicine | May 6, 2020 | Volume: 9 | Issue: 13 | Pages: 4593-4602

10.1002/cam4.3039 | PMID 32374488 Get It

AbstractBackgroundOutcomes data regarding advanced synovial sarcoma (SS) and myxoid/round cell liposarcoma (MRCL) are limited, consisting primarily of retrospective series and post hoc analyses of clinical trials.MethodsIn this multi‐center retrospective study, data were abstracted from the medical records of 350 patients from nine sarcoma centers throughout the United States and combined into a registry. Patients with advanced/unresectable or metastatic SS (n = 249) or MRCL (n = 101) who received first‐line systemic anticancer therapy and had records of tumor imaging were included. Overall survival (OS), time to next treatment, time to distant metastasis, and progression‐free survival (PFS) were evaluated using the Kaplan‐Meier method and Cox regression.ResultsAt start of first‐line systemic anticancer therapy, 92.4% of patients with SS and 91.1% of patients with MRCL had metastatic lesions. However, 74.7% of patients with SS and 72.3% of patients with MRCL had ≥2 lines of systemic therapy. Median OS and median PFS from first‐line therapy for SS was 24.7 months (95% CI, 20.9‐29.4) and 7.5 months, respectively (95% CI, 6.4‐8.4). Median OS and median PFS from start of first‐line therapy for MRCL was 29.9 months (95% CI, 27‐44.6) and 8.9 months (95% CI 4.5‐12.0).ConclusionsTo the best of our knowledge, this is the largest retrospective study of patients with SS and MRCL. It provides an analysis of real‐world clinical outcomes among patients treated at major sarcoma cancer centers and could inform treatment decisions and design of clinical trials. In general, the survival outcomes for this selected population appear more favorable than in published literature.
Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung
Glod, John , Steinberg, Seth M. , Reinke, Denise K. , Pressey, Joseph G. , Mascarenhas, Leo , Federman, Noah , Marina, Neyssa , Chawla, Sant P. , Lagmay, Joanne , Goldberg, John, Milhem, Mohammed , Loeb, David M. , Butrynski, James E., Turpin, Brian , Staddon, Arthur P., Spunt, Sheri L. , Jones, Robin L. , Rodler, Eve T. , Schuetze, Scott M. , Okuno, Scott H. , Helman, Lee J. , Baird, Kristin , Steinberg, Seth M , Reinke, Denise , Pressey, Joseph G , Federman, Noah , Milhem, Mohammed M , Schuetze, Scott M , Okuno, Scott , Spunt, Sheri L , Jones, Robin L , Mascarenhas, Leo , Goldberg, John, Marina, Neyssa

Mayo Clinic

Sarcoma | May 1, 2020 | Volume: 2020 | Issue: No issue available | Pages: 1-6

10.1155/2020/7935475 | PMID 32398945 Get It

Purpose. Osteosarcoma is a rare cancer and a third of patients who have completed primary treatment will develop osteosarcoma recurrence. The Src pathway has been implicated in the metastatic behavior of osteosarcoma; about 95% of samples examined express Src or have evidence of downstream activation of this pathway. Saracatinib (AZD0530) is a potent and selective Src kinase inhibitor that was evaluated in adults in Phase 1 studies. The primary goal of this study was to determine if treatment with saracatinib could increase progression-free survival (PFS) for patients who have undergone complete resection of osteosarcoma lung metastases in a double-blinded, placebo-controlled trial. Patients and Methods. Subjects with recurrent osteosarcoma localized to lung and who had complete surgical removal of all lung nodules were randomized within six weeks after complete surgical resection. Saracatinib, or placebo, was administered at a dose of 175 mg orally, once daily, for up to thirteen 28-day cycles. Results. Thirty-seven subjects were included in the analyses; 18 subjects were randomized to receive saracatinib and 19 to receive placebo. Intent-to-treat analysis demonstrated a median PFS of 19.4 months in the saracatinib treatment group and 8.6 months in the placebo treatment group (p=0.47). Median OS was not reached in either arm. Conclusions. Although saracatinib was well tolerated in this patient population, there was no apparent impact of the drug in this double-blinded, placebo-controlled trial on OS, and Src inhibition alone may not be sufficient to suppress metastatic progression in osteosarcoma. There is a suggestion of potential clinical benefit as evidenced by longer PFS in patients randomized to saracatinib based on limited numbers of patients treated.
Global injury morbidity and mortality from 1990 to 2017: results from the Global Burden of Disease Study 2017
James, Spencer L , Castle, Chris D, Dingels, Zachary V, Fox, Jack T, Hamilton, Erin B, Sylte, Dillon O , Henry, Nathaniel J , LeGrand, Kate E , Abdelalim, Ahmed , Abdulkader, Rizwan Suliankatchi , Abedi, Aidin , Eshete, Akine , Abushouk, Abdelrahman Ibrahim , Adebayo, Oladimeji , Agudelo‐Botero, Marcela , Ahmad, Tauseef , Aichour, Miloud Taki Eddine, Alahdab, Fares , Alamene, Genet Melak, Alanezi, Fahad , Alebel, Animut , Alema, Niguse Meles , Ali, Beriwan Abdulqadir, Alikhani, Mahtab , Alipour, Vahid, Almasri, Nihad A. , Altirkawi, Khalid A , Amer, Yasser Sami , Amini, Saeed, Amit, Arianna Maever L. , Andrei, Cătălina Liliana , Ansari-Moghaddam, Alireza, Antonio, Carl Abelardo T, Appiah, Seth Christopher Yaw , Arabloo, Jalal , Arefi, Zohreh , Aremu, Olatunde , Ariani, Filippo , Arora, Amit , Asghari, Babak , Awoke, Nefsu , Quintanilla, Beatriz Paulina Ayala , Ayano, Getinet , Ayanore, Martin Amogre , Azari, Samad , Azarian, Ghasem , Badawi, Alaa, Badiye, Ashish , Bagli, Eleni , Baig, Atif Amin , Bairwa, Mohan , Bakhtiari, Ahad , Banach, Maciej , Banerjee, Srikanta , Banik, Palash Chandra , Banstola, Amrit , Barker‐Collo, Suzanne , Bärnighausen, Till , Barrero, Lope H. , Barzegar, Akbar , Baye, Bayisa Abdissa , Bekuma, Tariku Tesfaye , Belete, Habte , Bennett, Derrick , Berhe, Kidanemaryam , Bhardwaj, Pankaj , Bhat, Anusha Ganapati , Bhattacharyya, Krittika , Bijani, Ali , Sayeed, Muhammad Shahdaat Bin , Borzì, Antonio Maria , Bražinová, Alexandra, Брико, Н. И. , Budhathoki, Shyam Sundar , Car, Josip , Cárdenas, Rosario , Carvalho, Félix , Castaldelli-Maia, João Maurício , Castañeda-Orjuela, Carlos A , Castelpietra, Giulio , Catalá-López, Ferrán , Cerin, Ester , Chandan, Joht Singh , Chanie, Wagaye Fentahun, Chattu, Soosanna Kumary , Chattu, Vijay Kumar , Chaudhary, Neha , Cho, Daniel , Chowdhury, Mohiuddin Ahsanul Kabir , Chu, Dinh‐Toi , Colquhoun, Samantha , Costa, Vera Marisa , Damiani, Giovanni , Dávila-Cervantes, Claudio Alberto , Demoz, Gebre Teklemariam , Demsie, Desalegn Getnet , Derakhshani, Afshin , Deribe, Kebede , Desai, Rupak , Nasab, Mostafa Dianati, Silva, Diana Dias da , Forooshani, Zahra Sadat Dibaji, Doyle, Kerrie , Driscoll, Tim , Dubljanin, Eleonora , Adema, Bereket Duko , Eagan, Arielle Wilder , Eftekhari, Aziz , Ehsani‐Chimeh, Elham , Elemineh, Demelash Abewa , El-Jaafary, Shaimaa I , El‐Khatib, Ziad , Ellingsen, Christian Lycke , Emamian, Mohammad Hassan , Endalew, Daniel Adane , Faris, Pawan , Faro, André , Farzadfar, Farshad , Fatahi, Yousef , Fekadu, Wubalem , Ferede, Tomas Y, Fereshtehnejad, Seyed‐Mohammad , Fernandes, Eduarda , Ferrara, Pietro , Feyissa, Garumma Tolu , Fischer, Florian , Foláyan, Morẹ́nikẹ́ Oluwátóyìn , Francis, Joel M , Fukumoto, Takeshi , Geberemariyam, Biniyam Sahiledengle, Gebre, Abadi Kahsu , Gebremedhin, Ketema Bizuwork , Gebremeskel, Gebreamlak Gebremedhn , Gebremichael, Berhe , Gedefaw, Getnet , Geta, Birhanu, Ghafourifard, Mansour , Ghamari, Farhad , Ghashghaee, Ahmad , Gholamian, Asadollah , Gill, Tiffany K, Goulart, Alessandra C. , Grada, Ayman , Gubari, Mohammed Ibrahim Mohialdeen , Guo, Yuming , Haagsma, Juanita A. , Hafezi‐Nejad, Nima , Hall, Brian J. , Hamadeh, Randah R , Hasan, Md. Mehedi , Hassen, Hamid Yimam , Havmoeller, Rasmus, Heydarpour, Fatemeh , Hı́jar, Martha , Ho, Hung Chak , Hoang, Chi Linh , Hole, Michael K., Hossain, Naznin , Hosseinzadeh, Mehdi , Hostiuc, Sorin , Ibitoye, Segun Emmanuel , Ilić, Irena , Ilić, Milena , Inbaraj, Leeberk Raja , Indriasih, Endang , Irvani, Seyed Sina Naghibi , Islam, Sheikh Mohammed Shariful , Islam, M. Mofizul , Ivers, Rebecca , Jacobsen, Kathryn H. , Jahani, Mohammad Ali, Jahanmehr, Nader , Jakovljević, Mihajlo , Jayaraman, Sudha , Jha, Ravi Prakash , John-Akinola, Yetunde O. , Joseph, Nitin , Joukar, Farahnaz, Jozwiak, Jacek Jerzy , Jürisson, Mikk , Kadel, Rajendra , Kahsay, Amaha , Kalankesh, Leila R , Kalhor, Rohollah , Kamil, Teshome Abegaz, Kapoor, Neeti , Karami, Manoochehr , Kasaeian, Amir , Kassaye, Hagazi Gebremedhin, Kavetskyy, Taras , Kebede, Hafte Kahsay , Keiyoro, Peter Njenga, Kelbore, Abraham Getachew , Kelkay, Bayew, Khader, Yousef , Khafaie, Morteza Abdullatif , Khalid, Nauman , Khalil, Ibrahim A, Khalilov, Rovshan , Khan, Ejaz Ahmad , Khan, Maseer , Khanna, Tripti, Shadmani, Fatemeh Khosravi , Khundkar, Roba , Kiirithio, Daniel N, Kim, Yun Jin , Kısa, Adnan , Kısa, Sezer , Komaki, Hamidreza , Kondlahalli, Shivakumar K M, Korshunov, Vladimir Andreevich , Kraemer, Moritz U. G. , Krishan, Kewal , Biçer, Burcu Küçük , Kugbey, Nuworza , Kumar, Vivek , Kumar, G Anil , Kumar, Manasi , Kumaresh, Girikumar, Kurmi, Om , Kuti, Oluwatosin, Lami, Faris , Lamichhane, Prabhat , Lang, Justin J. , Lasrado, Savita , Leasher, Janet L , Lee, Shaun Wen Huey , Lenjebo, Tsegaye Lolaso , Li, Shanshan , Linn, Shai , Liu, Xuefeng , Lunevičius, Raimundas , Lyons, Ronan A , Madadin, Mohammed , Razek, Muhammed Magdy Abd El, Mahotra, Narayan Bahadur , Majdán, Marek , Malagón-Rojas, Jeadran , Maled, Venkatesh , Manafi, Navid , Manafi, Amir , Manda, Ana-Laura, Mansour-Ghanaei, Fariborz, Mansouri, Borhan , March, Lyn , Mason‐Jones, Amanda J. , Masoumi, Seyedeh Zahra , Massenburg, Benjamin B. , Maulik, Pallab K , Meles, Gebrekiros Gebremichael , Melketsedik, Zeleke Aschalew , Memiah, Peter , Mendoza, Walter, Menezes, Ritesh G. , Mengesha, Melkamu Merid , Meretoja, Tuomo J , Meretoja, Atte , Merie, Hayimro Edemealem , Miazgowski, Bartosz , Miazgowski, Tomasz , Miller, Ted R. , Mini, GK , Мirrakhimov, Erkin М , Mirzaei-Alavijeh, Mehdi , Mithra, Prasanna , Moazen, Babak , Moghadaszadeh, Masoud, Mohammad, Yousef , Mohammad, Karzan Abdulmuhsin , Mezerji, Naser Mohammad Gholi, Mohammadian-Hafshejani, Abdollah , Mohammadoo-Khorasani, Milad, Mohammed, Shafiu , Mohammed, Jemal , Mohebi, Farnam , Molokhia, Mariam , Monasta, Lorenzo , Moodley, Yoshan , Moosazadeh, Mahmood , Moradi, Masoud , Moradi, Ghobad , Moradpour, Farhad , Morawska, Lídia , Velásquez, Ilais Moreno , Mossie, Tilahun Belete , Murthy, Srinivas , Musa, Kamarul Imran , Mustafa, Ghulam , Nabhan, Ashraf , Nagarajan, Ahamarshan Jayaraman , Naik, Gurudatta , Naimzada, Mukhammad David , Nangia, Vinay, Nascimento, Bruno Ramos , Naserbakht, Morteza , Ndwandwe, Duduzile , Negoi, Ionuţ , Ngunjiri, Josephine W, Nguyen, Cuong Tat , Nikbakhsh, Rajan , Ningrum, Dina Nur Anggraini , Nnaji, Chukwudi A , Nyasulu, Peter S. , Ogbo, Felix Akpojene , Oghenetega, Onome Bright , Okunga, Emmanuel , Olagunju, Andrew T , Olagunju, Tinuke O , Bali, Ahmed Omar , Onwujekwe, Obinna , Asante, Kwaku Oppong , Orpana, Heather , Otstavnov, Nikita , Otstavnov, Stanislav S , Mahesh, P A , Padubidri, Jagadish Rao , Pakhalé, Smita , Pakshir, Keyvan , Panda‐Jonas, Songhomitra, Park, Eun‐Kee , Patel, Sangram Kishor , Pathak, Ashish , Pati, Sanghamitra , Paulos, Kebreab , Pepito, Veincent Christian Filipino , Pham, Hai Quang , Pinheiro, Marina , Полибин, Р. В. , Polinder, Suzanne, Poustchi, Hossein, Prakash, Swayam , Pribadi, Dimas Ria Angga , Puri, Parul , Syed, Zahiruddin Quazi, Rabiee, Navid , Radfar, Amir , Rafay, Anwar, Rafiee, Ata , Rafiei, Alireza , Rahim, Fakher , Rahimi, Siavash , Rahimi‐Movaghar, Vafa , Rahman, Muhammad Aziz , Rajabpour-Sanati, Ali, Rajati, Fatemeh , Rakovac, Ivo , Ranganathan, Kavitha , Rao, Sowmya J, Rashedi, Vahid , Rastogi, Prateek , Rathi, Priya , Rawal, Lal , Rawassizadeh, Reza , Renjith, Vishnu , Renzaho, André M. N. , Resnikoff, Serge , Rezapour, Aziz, Rickard, Jennifer , Ríos-González, Carlos Miguel , Sabde, Yogesh , Saddik, Basema , Safari, Saeed , Safarpour, Hamid , Safdarian, Mahdi , Sajadi, S. Mohammad , Salamati, Payman, Salehi, Farkhonde , Zahabi, Saleh Salehi , Salem, Marwa Rashad , Salem, Hosni , Salman, Omar , Salz, Inbal, Samy, Abdallah M , Sanabria, Juan , Sànchez-Riera, Lídia , Santric-Milicevic, Milena M , Sarveazad, Arash , Sathian, Brijesh , Sawhney, Monika, Sawyer, Susan M. , Saxena, Sonia , Schwebel, David C. , Seedat, Soraya , Senthilkumaran, Subramanian , Seyedmousavi, Seyedmojtaba , Sha, Feng , Shaahmadi, Faramarz , Shaikh, Masood Ali , Shams-Beyranvand, Mehran , Shamsizadeh, Morteza , Sharif-Alhoseini, Mahdi , Sharifi, Hamid , Sheikh, Aziz , Shigematsu, Mika, Shin, Jae Il , Shiri, Rahman , Sigfúsdóttir, Inga Dóra, Singh, Pankaj Kumar , Sinha, Dhirendra Narain , Smarandache, Catalin-Gabriel , Soleymani, Bija, Soriano, Joan B. , Soyiri, Ireneous N , Stein, Dan J. , Sufiyan, Mu’awiyyah Babale , Suleria, Hafiz Ansar Rasul , Sykes, Bryan L. , Tabarés‐Seisdedos, Rafael , Tabb, Karen M. , Wogayehu, Biruk , Tamiru, Animut Tagele , Tarigan, Ingan Ukur , Tefera, Yibekal Manaye , Tekle, Merhawi Gebremedhin , Tekulu, Gebretsadkan Hintsa , Kassie, Ayenew , Bedaso, Asres , Tlaye, Kenean Getaneh , Tohidinik, Hamid Reza , Topór-Mądry, Roman , Tripathy, Jaya Prasad , Tsai, Alexander C. , Car, Lorainne Tudor , Ullah, Saif , Ullah, Irfan , Umar, Maida, Unnikrishnan, Bhaskaran , Upadhyay, Era , Valdéz, Pascual , Violante, Francesco Saverio , Waheed, Yasir , Teklay, Girmay , Werdecker, Andrea , Wiangkham, Taweewat , Wolde, Haileab Fekadu , Woldeyes, Dawit Habte , Yadav, Rajaram , Yadollahpour, Ali , Yano, Yuichiro , Yaya, Sanni , Yazdi‐Feyzabadi, Vahid , Yisma, Engida , Yoon, Seok‐Jun , Youm, Yoosik , Younis, Mustafa Z , Yousefi, Zabihollah , Yu, Yong , Yusefzadeh, Hasan, Moghadam, Telma Zahirian , Zaman, Sojib Bin , Zamanian, Maryam , Zhang, Zhi-Jiang , Zhang, Yunquan , Zodpey, Sanjay , Dandona, Lalit , Dandona, Rakhi , Hay, Simon I , Mokdad, Ali H. , Reiner, Robert C. , Sartorius, Benn , Vos, Theo , Topór‐Mądry, Roman , Zahiruddin, Quazi Syed , Dianatinasab, Mostafa , Sanati, Ali Rajabpour , Baig, Atif Amin , Kumar, Vivek , Stein, Dan J , Castaldelli-Maia, João M , Farzadfar, Farshad , Shin, Jae I L , Islam, Sheikh Mohammed Shariful , Rahman, Muhammad Aziz , Belete, T , Liu, Zichen, Roberts, Nicholas L S , Abdoli, Amir , Abdollahpour, Ibrahim , Ahmed, Rushdiá , Ahmed, Muktar Beshir , Alghnam, Suliman Abdullah , Al‐Hajj, Samar , Ali, Saqib , Alinia, Cyrus , Aljunid, Syed Mohamed , Almasi‐Hashiani, Amir , Amini, Saeed, Antonio, Carl Abelardo T. , Arab-Zozani, Morteza , Asaad, Malke , Balachandran, Arun , Bayati, Mohsen , Bedi, Neeraj , Behzadifar, Masoud , Benjet, Corina L. , Benseñor, Isabela M. , Bibi, Sadia , Borges, Guilherme , Boufous, Soufiane , Chatziralli, Irini , Constantin, María Magdalena , Daryani, Ahmad , Demeke, Feleke Mekonnen , Demis, Asmamaw , Forooshani, Zahra Sadat Dibaji, Duko, Bereket , Zaki, Maysaa El Sayed , Adane, Daniel, Eskandarieh, Sharareh , Yeheyis, Tomas Y. , Filip, Irina , Foroutan, Masoud , Franklin, Richard C. , Gill, Tiffany K. , Grivna, Michal , Guimarães, Rafael Alves , Gupta, Gaurav Kumar , Haghparast‐Bidgoli, Hassan , Hamidi, Samer , Haro, Josep María , Hasanzadeh, Amir , Hassanipour, Soheil , Hassankhani, Hadi , Hayat, Khezar , Hendrie, Delia V. , Holla, Ramesh , Hu, Guoqing , Ilesanmi, Olayinka Stephen , Jalilian, Farzad , Jayatilleke, Achala Upendra , Jonas, Jost B , Jungari, Suresh Banayya , Kabir, Ali , Kanchan, Tanuj , Rade, Bayew Kelkay , Khalil, Ibrahim A, Khammarnia, Mohammad , Khazaie, Habibolah , Kim, Young‐Eun , Kim, Daniel , Shivakumar, KM , Koyanagi, Ai , Kumar, Nithin , Vecchia, Carlo La , Lansingh, Van Charles , Laryea, Dennis Odai , Latifi, Arman , Lauriola, Paolo , Levi, Miriam , Lopez, Alan D , Lotufo, Paulo A. , Majeed, Azeem , Malekzadeh, Reza , Malta, Déborah Carvalho , Manjunatha, Narayana , Mansour‐Ghanaei, Fariborz , Mansournia, Mohammad Alì , Maravilla, Joemer Calderon , Melese, Addisu Dagnaw , Aschalew, Zeleke , Mengesha, Meresa Berwo , Meštrović, Tomislav , Mirică, Andreea , Mohamadi, Efat , Darwesh, Aso Mohammad , Mohammadpourhodki, Reza , Moradi‐Lakeh, Maziar , Morisaki, Naho , Morrison, Shane D. , Muluneh, Atalay Goshu , Najafi, Farid , Nayak, Vinod C , Nguyen, Huong Lan Thi , Oh, In‐Hwan , Ota, Erika , Patton, George , Peden, Amy E. , Pereira, Jeevan , Phillips, Michael , Rabiee, Mohammad , Rawaf, Salman , Ribeiro, Ana Isabel , Ronfani, Luca , Roshandel, Gholamreza , Saad, Anas M. , Sabour, Siamak , Safari‐Faramani, Roya , Salamati, Payman, Sarker, Abdur Razzaque , Sayyah, Mehdi , Sepanlou, Sadaf Ghajarieh , Shahabi, Saeed , Siabani, Soraya , Singh, Jasvinder A. , Smith, Emma U.R. , Soheili, Amin , Soltanian, Ali Reza , Sorrie, Muluken Bekele , Stokes, Mark Andrew , Tadesse, Degena Bahrey , Tehrani‐Banihashemi, Arash , Tesfay, Berhe Etsay , Thapar, Rekha , Tran, Bach Xuan , Tran, Khanh Bao , Uthman, Olalekan Abdulrahman , Vasankari, Tommi Juhani , Venketasubramanian, Narayanaswamy , Vlassov, Vasily , Wondafrash, Dawit Zewdu , Wondmeneh, Temesgen Gebeyehu , Wondmieneh, Adam Belay , Wu, Aimin , YIP, PAUL S. F. , Yonemoto, Naohiro , Yu, Chuanhua , Zaidi, Zoubida , Zamani, Mohammad , Zandian, Hamed , Zarei, Ahmad , Zare, Fatemeh, Degenhardt, Louisa J , Dharmaratne, Samath Dhamminda , Olagunju, Andrew T , Baig, Atif Amin , Desai, Rupak , Alahdab, Fares , Rahim, Fakher

Mayo Clinic

Injury Prevention | April 24, 2020 | Volume: 26 | Issue: Suppl 2 | Pages: i96-i114

10.1136/injuryprev-2019-043494 | PMID 32332142 Get It

Background Past research in population health trends has shown that injuries form a substantial burden of population health loss. Regular updates to injury burden assessments are critical. We report Global Burden of Disease (GBD) 2017 Study estimates on morbidity and mortality for all injuries. Methods We reviewed results for injuries from the GBD 2017 study. GBD 2017 measured injury-specific mortality and years of life lost (YLLs) using the Cause of Death Ensemble model. To measure non-fatal injuries, GBD 2017 modelled injury-specific incidence and converted this to prevalence and years lived with disability (YLDs). YLLs and YLDs were summed to calculate disability-adjusted life years (DALYs). Findings In 1990, there were 4 260 493 (4 085 700 to 4 396 138) injury deaths, which increased to 4 484 722 (4 332 010 to 4 585 554) deaths in 2017, while age-standardised mortality decreased from 1079 (1073 to 1086) to 738 (730 to 745) per 100 000. In 1990, there were 354 064 302 (95% uncertainty interval: 338 174 876 to 371 610 802) new cases of injury globally, which increased to 520 710 288 (493 430 247 to 547 988 635) new cases in 2017. During this time, age-standardised incidence decreased non-significantly from 6824 (6534 to 7147) to 6763 (6412 to 7118) per 100 000. Between 1990 and 2017, age-standardised DALYs decreased from 4947 (4655 to 5233) per 100 000 to 3267 (3058 to 3505). Interpretation Injuries are an important cause of health loss globally, though mortality has declined between 1990 and 2017. Future research in injury burden should focus on prevention in high-burden populations, improving data collection and ensuring access to medical care.
Factors Associated With Large Improvements in Health-Related Quality of Life in Patients With Atrial Fibrillation
Holmes, DaJuanicia N. , Pieper, Karen S. , Ezekowitz, Michael D. , Fonarow, Gregg C. , Gersh, Bernard J. , Kowey, Peter R. , Mahaffey, Kenneth W. , Reiffel, James A. , Singer, Daniel E. , Piccini, Jonathan P. , Mendelson, R. A., NEUTEL, J, Pan, Dengji, Poock, James J., Raffetto, J.D., Greengold, R., Roan, P G, Saba, F., Sackett, Melanie K., Schneider, R., Seymour, Zachary , Shanes, Jeffrey G., Smiley, Nasser, Smith, David H. , Snipes, C., Sotolongo, Rodolfo, Staniloae, Cezar , Stoltz, S., Suresh, D.P. , Tak, Tahir , Tannenbaum, A., Turk, Samir, Vora, Kishor, Randhawa, P., Zebrack, James S., Silva, Eduardo , Riley, Edward T., Weinstein, D., Vasiliauskas, Tomas, Goldbarg, Seth , Yarlagadda, Chakri, Laurion, D., Osunkoya, A., Burns, Richéal , Castor, Tatsiana , Luttman, C., Anton, Stephen D. , McGarvey, Jeremy R., Guthrie, Robert D., Deriso, George T., Flood, Raymond, Fleischer, L H, Fierstein, J.S., Jacobs, George B., Adjei, Nasser, Akyea-Djamson, Ayim, Bacon, Jenny , Bedwell, Noel W., Berger, PB, Berry, Joni I., Bhagwat, Ravi, Boccalandro, Fernando , Capó, Jaïr Dilmé, Kapadia, Sumit, Casanova, Rene, Morriss, J.E., Elsen, J., Farsad, Ramin, Fox, David J. , Frandsen, Brad, Gelernt, M., Hall, Cassandra L. , Hotchkiss, David R. , Ip, J., Jaffrani, Naseem, Kazmierski, John F., Waxman, F., Kneller, G. Larsen, Labroo, Ajay, Jaffe, Bernard M., Lebenthal, Mark, Lillestol, Michael, Leclerc, Kenneth M. , Maccaro, Paul, Mayer, Nolan, Kozłowski, J , Benjamin, Sanford P., Detweiler, Robert, Igic, Petar, Jackson, Tatum, Pappas, Janine, Littlefield, Ryan , Frey, Anna , Vranian, Robert B., Long, W., Grena, Paul, Arouni, Amy , Quinn, John , Blonder, Ronald, Snyder, H., Slabic, S., Cohen, Kenneth D., Walthall, W. W., Snoddy, Brian, Alvarado, Olga Franco, Leach, Corinne L., Rothman, Steven A., Olatidoye, Abiodun G, Almahameed, Soufian , Rosenthal, Shelly, Reiter, William M., Thompson, T., Thew, Stephen, Kobayashi, Junji , Williams, M., Kramer, Joel H. , Latif, Sidrah , Rhee, B., Ruiz-Serrano, D., Stringam, Stanley, Wolok, K., Focil, Augusto, Butman, Samuel, Ingersoll, Henry, Borge, R. P., Al-Saghir, Y., Farris, Neil, Shore, Karen, Gornick, C., Eilat, P., Paliwal, Y., Mitra, Rito , Jingo, Ahmad, Aslam, Asma , Watson, Robert, Voyce, Stephen , Turakhia, Mintu P. , Goytia-Leos, D., Lurie, Miriam, Mallis, G., Strobel, John, Fisher, D M, Atieh, Mutaz I., Drabick, Andrew, Harman, Ece, Ashcraft, B., Krista, M., Videlefsky, A., Zayas, E. Rivera, Tan, A.E., Gersh, Bernard J , Turakhia, Mintu P , Steinberg, Benjamin A. , Allen, Larry A. , Chan, Paul S. , Freeman, James V. , Hylek, Elaine M. , Naccarelli, Gerald V. , Peterson, Eric D. , Mendelson, R., AL-NAHHAS, ADIL M. , Padanilam, B., Pan, D., Raffetto, J., Roan, P., Sackett, M., Seymour, Z., Shoemaker, J. Kevin , Simms, V., Tak, T., Riley, E., Weinstein, D., Hayward, D., Burns, R., Spiller, D., McGarvey, J., Guthrie, R., Flood, R., Aggarwal, R., Jacobs, G., Alfieri, A., Bacon, J., Berger, P., Berry, J., Bloom, S., Kapadia, S., Casanova, R., Christensen, T., Fox, D., Gill, S., Grubb, Søren , Hall, C., Harris, H., Hotchkiss, D., Jones, A., Lee, David S. , Kozlowski, J., Benjamin, S., Detweiler, R., Jackson, T., Littlefield, R., Long, W., Quinn, J., Browne, Kevin D. , Forman, Steven L. , Ebinger, Martin , Williams, David Michael , Stein, R., Kirkland, S., Cohen, K., Walthall, W., Davis, Keith L. , Alvarado, O., Leach, C., Sharma, Anand , Sutter, G., Reiter, W., Kobayashi, J., Kramer, J., Latif, S.A., Adler, Alma J , Butman, Samuel M. , Coats, Paul , Shore, K., Schwartz, M.B., Quinlan, E., Mitra, R., Aslam, A.A., Lurie, M., Atwater, Brett D. , Murray, John M. , Fisher, D., Landes, Reid D. , Harman, E., Zayas, E. Rivera

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | April 16, 2020 | Volume: 13 | Issue: 5 | Pages: No page available

10.1161/circep.119.007775 | PMID 32298144 Get It

Background: Atrial fibrillation (AF) adversely impacts health-related quality of life (hrQoL). While some patients demonstrate improvements in hrQoL, the factors associated with large improvements in hrQoL are not well described. Methods: We assessed factors associated with a 1-year increase in the Atrial Fibrillation Effect on Quality-of-Life score of 1 SD (≥18 points; 3× clinically important difference), among outpatients in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation I registry. Results: Overall, 28% (181/636) of patients had such a hrQoL improvement. Compared with patients not showing large hrQoL improvement, they were of similar age (median 73 versus 74, P =0.3), equally likely to be female (44% versus 48%, P =0.3), but more likely to have newly diagnosed AF at baseline (18% versus 8%; P =0.0004), prior antiarrhythmic drug use (52% versus 40%, P =0.005), baseline antiarrhythmic drug use (34.8% versus 26.8%, P =0.045), and more likely to undergo AF-related procedures during follow-up (AF ablation: 6.6% versus 2.0%, P =0.003; cardioversion: 12.2% versus 5.9%, P =0.008). In multivariable analysis, a history of alcohol abuse (adjusted OR, 2.41; P =0.01) and increased baseline diastolic blood pressure (adjusted OR, 1.23 per 10-point increase and >65 mm Hg; P =0.04) were associated with large improvements in hrQoL at 1 year, whereas patients with prior stroke/transient ischemic attack, chronic obstructive pulmonary disease, and peripheral arterial disease were less likely to improve ( P <0.05 for each). Conclusions: In this national registry of patients with AF, potentially treatable AF risk factors are associated with large hrQoL improvement, whereas less reversible conditions appeared negatively associated with hrQoL improvement. Understanding which patients are most likely to have large hrQoL improvement may facilitate targeting interventions for high-value care that optimizes patient-reported outcomes in AF. Registration: URL: http://www.clinicaltrials.gov . Unique identifier: NCT01165710.
Perioperative Anemia: Prevention, Diagnosis, and Management Throughout the Spectrum of Perioperative Care
Shore‐Lesserson, Linda , Shander, Aryeh , Patel, Sephalie Y. , Perelman, Seth , Guinn, Nicole R. , Warner, Matthew A.

Mayo Clinic

Anesthesia & Analgesia | March 13, 2020 | Volume: 130 | Issue: 5 | Pages: 1364-1380

10.1213/ane.0000000000004727 | PMID 32167979 Get It

Anemia is common in the perioperative period and is associated with poor patient outcomes. Remarkably, anemia is frequently ignored until hemoglobin levels drop low enough to warrant a red blood cell transfusion. This simplified transfusion-based approach has unfortunately shifted clinical focus away from strategies to adequately prevent, diagnose, and treat anemia through direct management of the underlying cause(s). While recommendations have been published for the treatment of anemia before elective surgery, information regarding the design and implementation of evidence-based anemia management strategies is sparse. Moreover, anemia is not solely a concern of the preoperative encounter. Rather, anemia must be actively addressed throughout the perioperative spectrum of patient care. This article provides practical information regarding the implementation of anemia management strategies in surgical patients throughout the perioperative period. This includes evidence-based recommendations for the prevention, diagnosis, and treatment of anemia, including the utility of iron supplementation and erythropoiesis-stimulating agents (ESAs).
Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia
Kim, Soyoung , Tecca, Heather R. , Bo‐Subait, Stephanie, Brazauskas, Ruta , Buchbinder, David , Hamilton, Betty K. , Majhail, Navneet S. , Shaw, Peter J. , Marks, David I. , Litzow, Mark R. , Inamoto, Yoshihiro , DeFilipp, Zachariah , Hildebrandt, Gerhard , Olsson, Richard F. , Kasow, Kimberly A. , Rotz, Seth J. , Badawy, Sherif M. , Bhatt, Neel S. , Page, Kristin , Arellano, Martha , Kent, Michael , Farhadfar, Nosha , Seo, Sachiko , Hematti, Peiman , Freytes, César O. , Ganguly, Siddhartha , Nathan, Sunita , Burns, Linda J. , Shaw, Bronwen E. , Muffly, Lori , Olsson, Richard F , Majhail, Navneet S , Badawy, Sherif M , Muffly, Lori , Bhatt, Neel S , Kim, Soyoung , Hematti, Peiman , Lee, Catherine J , Phelan, Rachel , Battiwalla, Minoo , Lazarus, Hillard M. , Chhabra, Saurabh , Liesveld, Jane L. , Yared, Jean A. , Rovó, Alicia

Mayo Clinic

Blood Advances | March 13, 2020 | Volume: 4 | Issue: 6 | Pages: 983-992

10.1182/bloodadvances.2019001126 | PMID 32168378 Get It

Abstract There is marked paucity of data regarding late effects in adolescents and young adults (AYAs) who undergo myeloablative conditioning (MAC) allogeneic hematopoietic cell transplantation (HCT) for acute myeloid leukemia (AML). We evaluated late effects and survival in 826 1-year disease-free survivors of MAC HCT for AYA AML, with an additional focus on comparing late effects based upon MAC type (total body irradiation [TBI] vs high-dose chemotherapy only). The estimated 10-year cumulative incidence of subsequent neoplasms was 4% (95% confidence interval [CI], 2%-6%); 10-year cumulative incidence of nonmalignant late effects included gonadal dysfunction (10%; 95% CI, 8%-13%), cataracts (10%; 95% CI, 7%-13%), avascular necrosis (8%; 95% CI, 5%-10%), diabetes mellitus (5%; 95% CI, 3%-7%), and hypothyroidism (3%; 95% CI, 2%-5%). Receipt of TBI was independently associated with a higher risk of cataracts only (hazard ratio [HR], 4.98; P &lt; .0001) whereas chronic graft-versus-host disease (cGVHD) was associated with an increased risk of cataracts (HR, 3.22; P = .0006), avascular necrosis (HR, 2.49; P = .006), and diabetes mellitus (HR, 3.36; P = .03). Estimated 10-year overall survival and leukemia-free survival were 73% and 70%, respectively, and did not differ on the basis of conditioning type. In conclusion, late effects among survivors of MAC HCT for AYA AML are frequent and are more closely linked to cGVHD than type of conditioning.
Clinical outcomes from a retrospective registry of patients with locally advanced/metastatic synovial sarcoma and myxoid round cell liposarcoma.
Attia, Steven , Tine, Brian Andrew Van, Chawla, Sant P. , Druta, Mihaela , Bohac, Gerry C., Somaiah, Neeta , Pollack, Seth M. , Burgess, Melissa

Mayo Clinic

Journal of Clinical Oncology | March 12, 2020 | Volume: 37 | Issue: 15_suppl | Pages: e22520-e22520

10.1200/jco.2019.37.15_suppl.e22520 Get It

e22520 Background: Outcomes of patients (pts) with advanced synovial sarcoma (SS) and myxoid/round cell sarcoma (MRCL) is lacking. Current data is limited to single institution studies or post hoc analyses of clinical trials. To understand the natural history of these subtypes of soft tissue sarcoma we performed a systematic analysis of SS and MRCL patients from large medical institutions. Methods: Data was abstracted at 7 U.S. centers for pts treated from 2005 to 2015. Advanced SS or MRCL were eligible if they had received chemotherapy and were 18 years or older. The primary endpoint was overall survival, and secondary endpoints were progression free survival, time to next treatment, time to new distant metastasis. Results: 350 pts with locally advanced (LA), unresectable and/or or metastatic (Met) SS (n = 249) and MRCL (n = 101) were analyzed. The median age at diagnosis was 40 years for SS pts (58.2% male). The median age of MRCL pts was 50 years (67.3% male). 249 SS pts all had ≥ 1line of therapy, 74.7% had ≥2 lines of treatment. All MRCL pts received ≥1 line of treatment, 72.3% had ≥2 lines. The clinical outcomes (median overall survival (OS), progression free survival (PFS), time to next treatment (TTNT) and time to distant metastasis (TTDM)) from start of first-line chemotherapy are: The OS and PFS from second line chemotherapy decreased for all evaluable pts (n = 259) was 17.9 months (mos) [95% confidence interval (CI) (15.0, 22.3)]; 3.9 mos (3.4, 4.8), respectively. A similar trend toward shortened OS and PFS were seen with each subsequent line of chemotherapy. Conclusions: This registry analyzing real-world clinical outcomes among advanced SS and MRCL pts is the most comprehensive performed to date. It provides data on clinical outcomes depending on line of therapy and can provide the backbone for better patient management and design of future clinical trials.[Table: see text]